Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of CellProtect in Multiple Myeloma
NCT04558853Phase 1Unknown
- Sponsor
- Karolinska University Hospital
- Start
- Jan 2014
- Primary completion
- Dec 2021
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CellProtect in multiple myeloma (MM), sponsored by Karolinska University Hospital. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 6 months. Status: unknown.
02
Drugs
CellProtect
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04558853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04558853.